(EXPO) Exponent - Overview
Stock: Consulting, Analysis, Testing, Risk
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.57% |
| Yield on Cost 5y | 1.49% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 100.0% |
| Payout Ratio | 76.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 26.7% |
| Relative Tail Risk | -8.92% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.00 |
| Alpha | -30.88 |
| Character TTM | |
|---|---|
| Beta | 0.554 |
| Beta Downside | 0.242 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.55% |
| CAGR/Max DD | -0.29 |
Description: EXPO Exponent January 11, 2026
Exponent, Inc. (NASDAQ: EXPO) is a science- and engineering-consulting firm that serves a broad spectrum of industries through two operating segments: Engineering & Other Scientific, and Environmental & Health.
The Engineering segment delivers expertise in biomechanics, biomedical engineering, civil/structural engineering, data science, electrical/computer engineering, materials science, mechanical engineering, polymer chemistry, thermal sciences, and vehicle engineering. The Environmental & Health segment focuses on chemical regulation, food safety, ecological and biological sciences, environmental and earth sciences, and health sciences, plus proactive/reactive product safety, litigation support, and regulatory services.
Key customers span chemicals, construction, consumer products, energy, food & beverage, government, life sciences, insurance, manufacturing, technology, industrial equipment, and transportation, reflecting the firm’s diversified revenue base.
Recent performance highlights (FY 2023) include revenue of approximately $1.0 billion, an operating margin near 13 %, and a backlog exceeding $1.2 billion, indicating strong demand for consulting services amid heightened ESG compliance and rising product-liability litigation. The sector is further buoyed by increased regulatory scrutiny in chemicals and food safety, which drives steady growth for firms with deep technical expertise.
For a deeper quantitative assessment, you might explore ValueRay’s analyst notes on EXPO.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 104.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA -4.49 > 1.0 |
| NWC/Revenue: 45.86% < 20% (prev 49.17%; Δ -3.31% < -1%) |
| CFO/TA 0.17 > 3% & CFO 132.2m > Net Income 104.8m |
| Net Debt (-124.8m) to EBITDA (149.5m): -0.83 < 3 |
| Current Ratio: 2.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (51.5m) vs 12m ago -0.33% < -2% |
| Gross Margin: 40.33% > 18% (prev 0.45%; Δ 3989 % > 0.5%) |
| Asset Turnover: 75.90% > 50% (prev 75.12%; Δ 0.78% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z'' 8.29
| A: 0.34 (Total Current Assets 416.8m - Total Current Liabilities 154.8m) / Total Assets 761.4m |
| B: 0.87 (Retained Earnings 658.8m / Total Assets 761.4m) |
| C: 0.19 (EBIT TTM 144.5m / Avg Total Assets 752.8m) |
| D: 1.83 (Book Value of Equity 656.5m / Total Liabilities 358.6m) |
| Altman-Z'' Score: 8.29 = AAA |
Beneish M -2.87
| DSRI: 1.06 (Receivables 182.0m/168.6m, Revenue 571.4m/559.0m) |
| GMI: 1.11 (GM 40.33% / 44.60%) |
| AQI: 1.06 (AQ_t 0.26 / AQ_t-1 0.25) |
| SGI: 1.02 (Revenue 571.4m / 559.0m) |
| TATA: -0.04 (NI 104.8m - CFO 132.2m) / TA 761.4m) |
| Beneish M-Score: -2.87 (Cap -4..+1) = A |
What is the price of EXPO shares?
Over the past week, the price has changed by -3.22%, over one month by +2.28%, over three months by +7.99% and over the past year by -20.85%.
Is EXPO a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the EXPO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 90.3 | 25.7% |
| Analysts Target Price | 90.3 | 25.7% |
| ValueRay Target Price | 71.7 | -0.3% |
EXPO Fundamental Data Overview February 01, 2026
P/E Forward = 32.0513
P/S = 6.8334
P/B = 8.8528
P/EG = 3.14
Revenue TTM = 571.4m USD
EBIT TTM = 144.5m USD
EBITDA TTM = 149.5m USD
Long Term Debt = 82.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.49m USD (from shortTermDebt, last quarter)
Debt = 82.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -124.8m USD (from netDebt column, last quarter)
Enterprise Value = 3.50b USD (3.63b + Debt 82.6m - CCE 207.4m)
Interest Coverage Ratio = unknown (Ebit TTM 144.5m / Interest Expense TTM 0.0)
EV/FCF = 28.52x (Enterprise Value 3.50b / FCF TTM 122.9m)
FCF Yield = 3.51% (FCF TTM 122.9m / Enterprise Value 3.50b)
FCF Margin = 21.51% (FCF TTM 122.9m / Revenue TTM 571.4m)
Net Margin = 18.35% (Net Income TTM 104.8m / Revenue TTM 571.4m)
Gross Margin = 40.33% ((Revenue TTM 571.4m - Cost of Revenue TTM 340.9m) / Revenue TTM)
Gross Margin QoQ = 24.94% (prev 16.43%)
Tobins Q-Ratio = 4.60 (Enterprise Value 3.50b / Total Assets 761.4m)
Interest Expense / Debt = 7.77% (Interest Expense 6.42m / Debt 82.6m)
Taxrate = 27.38% (10.6m / 38.6m)
NOPAT = 105.0m (EBIT 144.5m * (1 - 27.38%))
Current Ratio = 2.69 (Total Current Assets 416.8m / Total Current Liabilities 154.8m)
Debt / Equity = 0.21 (Debt 82.6m / totalStockholderEquity, last quarter 402.9m)
Debt / EBITDA = -0.83 (Net Debt -124.8m / EBITDA 149.5m)
Debt / FCF = -1.02 (Net Debt -124.8m / FCF TTM 122.9m)
Total Stockholder Equity = 423.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.93% (Net Income 104.8m / Total Assets 761.4m)
RoE = 24.77% (Net Income TTM 104.8m / Total Stockholder Equity 423.3m)
RoCE = 28.57% (EBIT 144.5m / Capital Employed (Equity 423.3m + L.T.Debt 82.6m))
RoIC = 24.79% (NOPAT 105.0m / Invested Capital 423.3m)
WACC = 7.91% (E(3.63b)/V(3.71b) * Re(7.96%) + D(82.6m)/V(3.71b) * Rd(7.77%) * (1-Tc(0.27)))
Discount Rate = 7.96% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF Debug] Terminal Value 78.08% ; FCFF base≈135.1m ; Y1≈131.9m ; Y5≈132.9m
Fair Price DCF = 50.43 (EV 2.39b - Net Debt -124.8m = Equity 2.52b / Shares 49.9m; r=7.91% [WACC]; 5y FCF grow -3.46% → 2.90% )
EPS Correlation: -36.60 | EPS CAGR: -48.68% | SUE: -4.0 | # QB: 0
Revenue Correlation: 66.19 | Revenue CAGR: 3.89% | SUE: 1.02 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.55 | Chg30d=+0.002 | Revisions Net=+2 | Analysts=3
EPS next Year (2026-12-31): EPS=2.25 | Chg30d=+0.018 | Revisions Net=+3 | Growth EPS=+9.3% | Growth Revenue=+8.2%